# Sidera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sidera

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.siderabio.com/
- Total disclosed funding: $109M
- Latest round: Series A (Dec 8, 2025)
- Investors on record: 4

## About

Sidera, based in Copenhagen, Denmark, specializes in developing transformative therapies for cardiometabolic disorders by leveraging advancements in human genetics to create innovative medications aimed at improving patient outcomes. Founded in Copenhagen, Denmark, Sidera focuses on developing therapies for cardiometabolic diseases. The company has engaged in one significant funding round, raising USD 109.00 mn in Series A funding on December 8, 2025, with contributions from Forbion, Gilde Healthcare, Novo Holdings, and RA Capital. No known pivots or changes in the business strategy have been noted. Sidera specializes in developing transformative cardiometabolic therapies by harnessing advancements in human genetics. The company focuses on creating innovative medications aimed at addressing a range of cardiometabolic disorders, including conditions like diabetes, obesity, and cardiovascular diseases. Sidera's therapeutics are designed to improve patient outcomes by targeting the root causes of these conditions, ultimately enhancing quality of life. The company serves a diverse client base, including healthcare providers, research institutions, and pharmaceutical companies, with its products aimed at markets in North America and Europe. By leveraging genetic insights, Sidera is positioned to address unmet medical needs within these geographical areas.Sidera operates on a business model that includes partnerships with healthcare organizations and pharmaceutical companies for its innovative therapies. The revenue generation occurs through these partnerships, which may include licensing agreements and joint research initiatives, leveraging the company's proprietary technologies. The company's flagship products are anticipated to enter the market through direct channels to health systems and specialized distributors, facilitating streamlined access for healthcare providers and their patients. Specific pricing strategies for the therapies are established during negotiations with partners, ensuring competitive positioning within the cardiometabolic treatment landscape. Sidera plans to use the USD 109.00 mn raised in Series A funding to support its product and platform development activities. The company is focused on launching new therapies designed for cardiometabolic conditions, further expanding its reach into North American and European markets. As part of its growth strategy, Sidera aims to develop additional innovative solutions aimed at addressing the needs of patients suffering from these prevalent disorders.

## Funding rounds

- Series A, Dec 8, 2025, $109M — Gilde Healthcare, Novo Holdings, Forbion, RA Capital Management

## Investors

- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A
- Novo Holdings — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A